Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments (PROPHETIC Trial)
Recruiting in Palo Alto (17 mi)
+40 other locations
Overseen ByWilliam P Fusselman, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: OncoHost Ltd.
No Placebo Group
Trial Summary
What is the purpose of this trial?This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Eligibility Criteria
Participant Groups
5Treatment groups
Experimental Treatment
Group I: SCLC stage IVExperimental Treatment1 Intervention
Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
Group II: Newly diagnosed NSCLC stage IVExperimental Treatment1 Intervention
Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
Group III: NSCLC stage IV 2nd line and further of immunotherapyExperimental Treatment1 Intervention
Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
Group IV: Malignant melanoma stage IVExperimental Treatment1 Intervention
Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
Group V: Malignant melanoma stage IIIb-dExperimental Treatment1 Intervention
Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Helen Nassif Community Cancer CenterCedar Rapids, IA
Northwest Community HealthcareRolling Meadows, IL
Michael E. Debakey VA Medical CenterHouston, TX
151-Christus Health St. MichaelTexarkana, TX
More Trial Locations
Loading ...
Who is running the clinical trial?
OncoHost Ltd.Lead Sponsor